About: Challenges in severe community-acquired pneumonia: a point-of-view review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Challenges in severe community-acquired pneumonia: a point-of-view review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Challenges in severe community-acquired pneumonia: a point-of-view review
Creator	Martin-Loeches, Ignacio Torres, Antoni Chalmers, James Kollef, Marin Wunderink, Richard Niederman, Michael Dominedò, Cristina Cruz, Charles
Source	PMC
abstract	PURPOSE: Severe community-acquired pneumonia (SCAP) is still associated with substantial morbidity and mortality. In this point-of-view review paper, a group of experts discuss the main controversies in SCAP: the role of severity scores to guide patient settings of care and empiric antibiotic therapy; the emergence of pathogens outside the core microorganisms of CAP; viral SCAP; the best empirical treatment; septic shock as the most lethal complication; and the need for new antibiotics. METHODS: For all topics, the authors describe current controversies and evidence and provide recommendations and suggestions for future research. Evidence was based on meta-analyses, most recent RCTs and recent interventional or observational studies. Recommendations were reached by consensus of all the authors. RESULTS AND CONCLUSIONS: The IDSA/ATS criteria remain the most pragmatic tool to predict ICU admission. The authors recommend a combination of a beta-lactam/beta-lactamase inhibitor or a third G cephalosporin plus a macrolide in most SCAP patients, and to empirically cover PES (P. aeruginosa, extended spectrum beta-lactamase producing Enterobacteriaceae, methicillin-resistant S. aureus) pathogens when at least two specific risk factors are present. In patients with influenza CAP, the authors recommend the use of oseltamivir and avoidance of the use of steroids. Corticosteroids can be used in case of refractory shock and high systemic inflammatory response.
has issue date	2019-01-31(xsd:dateTime)
bibo:doi	10.1007/s00134-019-05519-y
bibo:pmid	30706119
has license	no-cc
sha1sum (hex)	141b49f60097a85275850ceeb9fc97e58000d039
schema:url	https://doi.org/10.1007/s00134-019-05519-y
resource representing a document's title	Challenges in severe community-acquired pneumonia: a point-of-view review
has PubMed Central identifier	PMC7094947
has PubMed identifier	30706119
schema:publication	Intensive Care Med
resource representing a document's body	covid:141b49f60097a85275850ceeb9fc97e58000d039#body_text
is schema:about of	named entity 'septic shock' named entity 'lethal' named entity 'substantial' named entity 'complication' named entity 'care' named entity 'empirical treatment' named entity 'EMPIRICAL TREATMENT' named entity 'SCAP' named entity 'BEST' named entity 'scores' named entity 'empiric' named entity 'group' named entity 'viral' named entity 'community-acquired pneumonia' named entity 'pathogens' named entity 'microorganisms' named entity 'SCAP' named entity 'pathogens' named entity 'mortality' named entity 'pandemics' named entity 'clinical study' named entity 'ICU' named entity 'SCAP' named entity 'pathogens' named entity 'pathogens' named entity 'chronic respiratory diseases' named entity 'microbiology' named entity 'Septic shock' named entity 'SCAP' named entity 'viral infection' named entity 'bacterial resistance' named entity 'necrotizing' named entity 'meta-analyses' named entity 'beta-lactams' named entity 'Biomarkers' named entity 'risk factors' named entity 'community-acquired pneumonia' named entity 'microorganisms' named entity 'practice guidelines' named entity 'A major' named entity 'risk factors' named entity 'Cochrane' named entity 'safety profile' named entity 'septic shock' named entity 'intravenous' named entity 'pathogens' named entity 'pathogen' named entity 'pathogen' named entity 'pathogens' named entity 'SCAP' named entity 'intensive care' named entity 'K. pneumoniae' named entity 'pathogens' named entity 'risk factors' named entity 'vasopressor' named entity 'CURB65' named entity 'observational study' named entity 'phase 2 trial' named entity 'pathogens' named entity 'meta-analyses' named entity 'SCAP' named entity 'observational studies' named entity 'quinolone' named entity 'combination therapy' named entity 'HCAP' named entity 'ribosomal subunit' named entity 'MRSA' named entity 'clinical practice' named entity 'severe sepsis' named entity 'active form' named entity 'P. aeruginosa' named entity 'risk factors' named entity 'nosocomial' named entity 'RCT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software